NCT05475522: Intraoperative Sonographically Versus Fluorescence-guided Resection of Contrast-enhancing Gliomas and Brain Metastases

NCT05475522
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 79 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT05475522

Comments are closed.

Up ↑